[Skip to Content]
[Skip to Content Landing]
July 31, 1967

The Treatment of Hyperthyroidism

JAMA. 1967;201(5):330. doi:10.1001/jama.1967.03130050064026

To the Editor:—  In the editorial of April 10, the author states, "Every major center uses repeated doses of 131I.... and this often requires doses in excess of 100 mc and four or more doses." In my report1 including toxic nodular goiters, 1,101 patients received fewer than four doses, 86 received four and 63 more than four. As our experience is increased, the need for these multiple doses has decreased markedly. Doses of 10 mc or less were received by 596 patients, 180 received between 10 and 20 mc, and 76 between 20 and 30 mc. This hardly justifies a statement that doses in excess of 100 mc are often required.No one denies that the incidence of myxedema is high after 131I therapy, but this is the only proved undesirable result and one that is readily treated by replacement therapy.The editorial avoids the problems encountered